City of Hope's Department of Cancer Biology has two over-arching goals:
to develop powerful approaches to cancer prevention; and
to improve diagnostic tools for detecting cancer early, when it is most treatable.
The research team studies the physical and chemical processes of cancer development (known as carcinogenesis), and investigates the work of genes – understanding the basic mechanisms of genetics, gene expression and function, signaling pathways, mutagenesis, DNA repair, and epigenetics – specifically as they relate to the development and progression of cancer.
The Department offers scientists a multidisciplinary research and training environment in a number of scientific areas, including:
Cancer Prevention and Diagnosis
Developmental Biology Drug Resistance
Epigenetics Hormonal Carcinogenesis
Working to eliminate cancer through prevention, treatment, and cures, researchers in the Department of Cancer Biology work jointly, not only with other clinical and basic research teams within City of Hope, but also with other research centers, nationally and internationally. In the battle against cancer, the Department is another mighty weapon in City of Hope’s arsenal.
Dr. Chen has studied the role of aromatase in breast cancer development for more than 20 years. Currently Dr. Chen's research explores the mechanisms of endocrine resistance in breast cancer cells and seeks to understand the structure-function relationship of the aromatase protein in order to develop chemoprevention strategies using phytochemicals with anti-aromatase activity. His laboratory also investigates the impact of environmental chemicals on human health by modulating aromatase activity and expression.
Dr. Chen's lab deciphers roles and functions of epigenetic regulators and determines their differential contribution to cancer and longevity, and through which, to develop approaches to improve cancer treatment, reduce cancer risk and promote healthy aging.
Dr. Jones lab focuses on translational research in Urologic Oncology, identifying drug targets and developing treatments for prostate and kidney cancer.
Dr. Kane’s lab studies the molecular and cellular mechanisms of drug resistance to learn more about mechanisms of action, why treatments fail and which patients will best respond to specific therapies.
Mei Kong, Ph.D.
– Associate Professor - Signal Transduction and Cancer Metabolism
Dr. Kong's research lab aims to delineate the strategies used by tumor cells to survive periods of metabolic stress and then to develop novel therapies targeting nutrient sensing pathways of neoplastic cells. Currently their research focuses on protein phosphatase 2A (PP2A) complexes in regulation of cancer cell survival upon nutrients deprivation.
Edward Newman, Ph.D.
– Associate Professor - Development of novel DNA methyltransferase inhibitors for cancer therapy. Co-leader, Development Cancer Therapeutics Program
Dr. Newman's research concentrates on developing novel DNA methyltransferase inhibitors for cancer therapy.
Dr. O'Connor's lab is interested in DNA repair mechanisms, the biological consequences of repair failure, exploiting DNA repair mechanisms for therapeutic benefit and how DNA repair mechanisms can be used to control the epigenome of cells.
Monoallelic expression is a characteristic of genes that are implicated in certain inherited disorders of the CNS as well as some cancers. Using clonal CNS-derived neural stem cells as a model system, Dr. Sam's group is studying possible mechanisms for such expression.
– Professor – Prostate Cancer, animal models
Dr. Sun’s research interest focuses on the molecular mechanisms underlying transcriptional control and cell signaling in development and tumorigenesis. His ongoing projects include using cutting edge mouse models and other in vivo and in vitro approaches to uncover gene-expression and genomic and epigenetic alterations during the course of tumor initiation and progression.
Timothy W. Synold, Pharm. D.
– Professor; Director, Analytical Pharmacology Core Facility and Director, Clinical Immunobiology Correlative Studies Laboratory
Dr. Synold is a clinical and molecular pharmacologist who serves as Director of the Analytical Pharmacology and Clinical Immunology Laboratories. He is also the Scientific Leader of the COH Phase I Clinical Trial team and Director of Pharmacology for the NCI-supported California Cancer Consortium (CCC). Dr. Synold has over 25 years experience in chemistry and pharmacology, and he is an expert in the fields of pharmacokinetics and pharmacodynamics. His current research focus involves the role of the blood-brain-barrier in CNS penetration of drugs